The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration

Cytotherapy

Volumn 18, Issue 1, 2016, Pages 13-24

  Konala, Vijay Bhaskar Reddy ^a,b   Mamidi, Murali Krishna ^c   Bhonde, Ramesh ^c   Das, Anjan Kumar ^d   Pochampally, Radhika ^e   Pal, Rajarshi ^c  

^a AMET UNIVERSITY   (India)

^b Genes and Life Health Care Pvt Ltd   (India)

^c MANIPAL UNIVERSITY   (India)

^d TAYLOR S UNIVERSITY   (Malaysia)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Cell therapy; Exosomes; Mesenchymal stromal cells; Regeneration; Secretome

Indexed keywords

CELL MOTION; CYTOLOGY; EXOSOME; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; REGENERATION; SECRETION (PROCESS); STEM CELL NICHE; TRANSLATIONAL RESEARCH;

CELL MOVEMENT; EXOSOMES; HUMANS; MESENCHYMAL STROMAL CELLS; REGENERATION; STEM CELL NICHE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84955357177     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.10.008     Document Type: Review

References (83)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8(9):726-762.
3. Shi Y., Hu G., Su J., Li W., Chen Q., Shou P., et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010, 20(5):510-518.
4. Davey G.C., Patil S.B., O'Loughlin A., O'Brien T. Mesenchymal stem cell-based treatment for microvascular and secondary complications of Diabetes mellitus. Front Endocrinol (Lausanne) 2014, 5:86.
5. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110(10):3499-3506.
6. Volarevic V., Al-Qahtani A., Arsenijevic N., Pajovic S., Lukic M.L. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010, 43(4):255-263.
7. Poncelet A.J., Vercruysse J., Saliez A., Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in-vitro, intra cardiac injection elicits an immune response in-vivo. Transplantation 2007, 83(6):783-790.
8. Schu S., Nosov M., O'Flynn L., Shaw G., Treacy O., Barry F., et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012, 16(9):2094-2103.
9. Griffin M.D., Ryan A.E., Alagesan S., Lohan P., Treacy O., Ritter T. Anti- donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013, 91(1):40-51.
10. Taran R., Mamidi M.K., Singh G., Dutta S., Parhar I.S., John J.P., et al. In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources. J Biosci 2014, 39(1):157-169.
11. Hsiao S.T., Asgari A., Lokmic Z., Sinclair R., Dusting G.J., Lim S.Y., et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev 2012, 21(12):2189-2203.
12. Lopatina T., Kalinina N., Karagyaur M., Stambolsky D., Rubina K., Revischin A., et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS ONE 2011, 6(3):e17899.
13. Wei X., Zhao L., Zhong J., Gu H., Feng D., Johnstone B.H., et al. Adipose stromal cells-secreted neuroprotective media against neuronal apoptosis. Neurosci Lett 2009, 462(1):76-79.
14. Lee S.T., Chu K., Jung K.H., Im W.S., Park J.E., Lim H.C., et al. Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 2009, 66(5):671-681.
15. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. A randomized, double-blind, placebo controlled dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) following acute myocardial infarction. J Am Coll Cardiol 2009, 54(24):2277-2286.
16. Llufriu S., Sepulveda M., Blanco Y., Marín P., Moreno B., Berenguer J., et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE 2014, 9(12):e113936.
17. Mudrabettu C., Kumar V., Rakha A., Yadav A.K., Ramachandran R., Kanwar D.B., et al. Safety and efficacy of autologous mesenchymal stromal cells transplantation in patients undergoing living donor kidney transplantation: a pilot study. Nephrology (Carlton) 2015, 20(1):25-33.
18. Díez-Tejedor E., Gutiérrez-Fernández M., Martínez-Sánchez P., Rodríguez-Frutos B., Ruiz-Ares G., Lara M.L., et al. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. J Stroke Cerebrovasc Dis 2014, 23(10):2694-2700.
19. Venkataramana N.K., Kumar S.K., Balaraju S., Radhakrishnan R.C., Bansal A., Dixit A., et al. Open-labeled study of unilateral autologous bone-marrow derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 2010, 155(2):62-70.
20. Kanafi M.M., Rajeshwari Y.B., Gupta S., Dadheech N., Nair P.D., Gupta P.K., et al. Transplantation of islet-like cell clusters derived from human dental pulp stem cells restores normoglycemia in diabetic mice. Cytotherapy 2013, 15(10):1228-1236.
21. Das A.K., Bin Abdullah B.J., Dhillon S.S., Vijanari A., Anoop C.H., Gupta P.K. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study. World J Surg 2013, 37(4):915-922.
22. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
23. Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34 hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34 progenitors to peripheral blood. J Exp Med 1997, 185:111-120.
24. Hong H.S., Lee J., Lee E., Kwon Y.S., Ahn W., Jiang M.H., et al. A new role of substance P as an injury-inducible messenger for mobilization of CD29() stromal-like cells. Nat Med 2009, 15:425-435.
25. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
26. Schenk S., Mal N., Finan A., Zhang M., Kiedrowski M., Popovic Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
27. Louridas M., Letourneau S., Lautatzis M.E., Vrontakis M. Galanin is highly expressed in bone marrow mesenchymal stem cells and facilitates migration of cells both in vitro and in vivo. Biochem Biophys Res Commun 2009, 390:867-871.
28. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4(3):206-216.
29. Chavakis E., Urbich C., Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008, 45(4):514-522.
30. Cho K.S., Park H.K., Park H.Y., Jung J.S., Jeon S.G., Kim Y.K., et al. IFATS collection: immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells 2009, 27(1):259-265.
31. Ries C., Egea V., Karow M., Kolb H., Jochum M., Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109(9):4055-4063.
32. Baek S.J., Kang S.K., Ra J.C. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med 2011, 43(10):596-603.
33. Rani S., Ryan A.E., Griffin M.D., Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 2015, 23(5):812-823.
34. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013, 200(4):373-383.
35. Gyorgy B., Szabo T.G., Pasztoi M., Pal Z., Misjak P., Aradi B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011, 68(16):2667-2688.
36. Lee Y., El Andaloussi S., Wood M.J. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012, 21:125-134.
37. Harding C., Heuser J., Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983, 97(2):329-339.
38. Sullivan R., Saez F., Girouard J., Frenette G. Role of exosomes in sperm maturation during the transit along the male reproductive tract. Blood Cells Mol Dis 2005, 35(1):1-10.
39. Lai R.C., Chen T.S., Lim S.K. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med 2011, 6(4):481-492.
40. Doeppner T.R., Herz J., Görgens A., Schlechter J., Ludwig A.K., Radtke S., et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med 2015, 4:1-13.
41. Yu B., Zhang X., Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014, 15(3):4142-4157.
42. Biancone L., Bruno S., Deregibus M.C., Tetta C., Camussi G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012, 27(8):3037-3042.
43. Clayton A. Cancer cells use exosomes as tools to manipulate immunity and the microenvironment. Oncoimmunology 2012, 1(7):78-80.
44. Eldh M., Ekstrom K., Valadi H., Sjöstrand M., Olsson B., Jernas M., et al. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS ONE 2010, 5(12):e15353.
45. Hugel B., Martinez M.C., Kunzelmann C., Freyssinet J.M. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005, 20:22-27.
46. Bang C., Thum T. Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol 2012, 44(11):2060-2064.
47. Chaput N., Thery C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011, 33(5):419-440.
48. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9(6):654-659.
49. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010, 4(3):214-222.
50. Peche H., Heslan M., Usal C., Amigorena S., Cuturi M.C. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 2003, 76(10):1503-1510.
51. Vishnubhatla I., Corteling R., Stevanato L., Hicks C., Sinden J. The development of stem cell-derived exosomes as a cell-free regenerative medicine. J Circ Biomark 2014, 3:2.
52. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20(5):847-856.
53. Bobis-Wozowicz S., Kmiotek K., Sekula M., Kedracka-Krok S., Kamycka E., Adamiak M., et al. Human induced pluripotent stem cell-derived microvesicles transmit RNAs and proteins to recipient mature heart cells modulating cell fate and behavior. Stem Cells 2015, 33(9):2748-2761.
54. Mathivanan S., Ji H., Simpson R.J. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010, 73(10):1907-1920.
55. Collino F., Deregibus M.C., Bruno S., Sterpone L., Aghemo G., Viltono L., et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS ONE 2010, 5(7):e11803.
56. Oerlemans M.I., Koudstaal S., Chamuleau S.A., de Kleijn D.P., Doevendans P.A., Sluijter J.P. Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. Int J Cardiol 2013, 165(3):410-422.
57. Coleman M.L., Sahai E.A., Yeo M., Bosch M., Dewar A., Olson M.F. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001, 3(4):339-345.
58. Camussi G., Deregibus M.C., Bruno S., Cantaluppi V., Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010, 78(9):838-848.
59. Yeo R.W., Lai R.C., Tan K.H., Lim S.K. Exosome: a novel and safer therapeutic refinement of mesenchymal stem cell. Exosomes and Microvesicles 2013, 1:7.
60. Webber J., Clayton A. How pure are your vesicles?. J Extracell Vesicles 2013, 10:2.
61. Feng Y., Huang W., Wani M., Yu X., Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS ONE 2014, 9(2):e88685.
62. Arslan F., Lai R.C., Smeets M.B., Akeroyd L., Choo A., Aguor E.N., et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 2013, 10(3):301-312.
63. Lee C., Mitsialis S.A., Aslam M., Vitali S.H., Vergadi E., Konstantinou G., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126(22):2601-2611.
64. Huang L., Ma W., Ma Y., Feng D., Chen H., Cai B. Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases?. Int J Biol Sci 2015, 11(2):238-245.
65. Yang T., Martin P., Fogarty B., Brown A., Schurman K., Phipps R., et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio Rerio. Pharm Res 2015, 32(6):2003-2014. Epub ahead of print.
66. Xin H., Li Y., Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci 2014, 8:377.
67. Tsilioni I., Panagiotidou S., Theoharides T.C. Exosomes in neurologic and psychiatric disorders. Clin Ther 2014, 36(6):882-888.
68. Pusic A.D., Pusic K.M., Kraig R.P. What are exosomes and how can they be used in multiple sclerosis therapy?. Expert Rev Neurother 2014, 14(4):353-355.
69. Zhou Y., Xu H., Xu W., Wang B., Wu H., Tao Y., et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 2013, 4(2):34.
70. Mokarizadeh A., Delirezh N., Morshedi A., Mosayebi G., Farshid A.A., Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett 2012, 147(1-2):47-54.
71. Zhang B., Yin Y., Lai R.C., Tan S.S., Choo A.B., Lim S.K. Mesenchymal stem cell secretes immunologically active exosomes. Stem Cells Dev 2014, 23(11):1233-1244.
72. Vallabhaneni K.C., Penfornis P., Dhule S., Guillonneau F., Adams K.V., Mo Y.Y., et al. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget 2015, 6(7):4953-4967.
73. Ono M., Kosaka N., Tominaga N., Yoshioka Y., Takeshita F., Takahashi R.U., et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 2014, 7(332). ra63.
74. Lee J.K., Park S.R., Jung B.K., Jeon Y.K., Lee Y.S., Kim M.K., et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE 2013, 8(12):e84256.
75. Kordelas L., Rebmann V., Ludwig A.K., Radtke S., Ruesing J., Doeppner T.R., et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014, 28(4):970-973.
76. Viaud S., Théry C., Ploix S., Tursz T., Lapierre V., Lantz O., et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res 2010, 70(4):1281-1285.
77. Andrews D.W., Resnicoff M., Flanders A.E., Kenyon L., Curtis M., Merli G., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001, 19(8):2189-2200.
78. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3(1):9.
79. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008, 16(4):782-790.
80. Escudier B., Dorval T., Chaput N., André F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived exosomes: results of the first phase I clinical trial. J Transl Med 2005, 3(1):10.
81. Salido-Guadarrama I., Romero-Cordoba S., Peralta-Zaragoza O., Hidalgo-Miranda A., Rodríguez-Dorantes M. MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther 2014, 7:1327-1338.
82. Bellingham S.A., Guo B.B., Coleman B.M., Hill A.F. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?. Front Physiol 2012, 3:124.
83. Ward P.A. The sepsis seesaw: seeking a heart salve. Nat Med 2009, 15(5):497-498.